The APGI is aiming to catalogue genomic abnormalities in pancreatic cancer using state of the art sequencing technologies. To do this, high quality well annotated biospecimens are required.
A key APGI priority is to continue to build capacity in translational research by acquiring biological material and clinico-pathological data for all types of pancreatic disease, which will provide an unparalleled base for ongoing studies. The APGI incorporates the NSW Pancreatic Cancer Network (2006-2010) and the Australian Familial Pancreatic Cancer Cohort (AFPaCC) (2011-2014).
The APGI has multiple sub-studies investigating different aspects of pancreatic cancer diagnosis and treatment. We are always looking for more people to be involved in our research studies. Click to find out more about our current studies.
The purpose of genome-wide survey of cancer cells is the identification of driver mutations which are key to the development of cancer at the cellular level.
The APGI has provided coded clinical data and biological resources to many institutions and researchers to help further pancreatic cancer research worldwide.
We are seeing great progress in pancreatic cancer research and the APGI and it's collaborators are at the heart of this.